SK287043B6 - Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie - Google Patents
Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie Download PDFInfo
- Publication number
- SK287043B6 SK287043B6 SK957-2001A SK9572001A SK287043B6 SK 287043 B6 SK287043 B6 SK 287043B6 SK 9572001 A SK9572001 A SK 9572001A SK 287043 B6 SK287043 B6 SK 287043B6
- Authority
- SK
- Slovakia
- Prior art keywords
- brivudine
- treatment
- magnesium stearate
- microcrystalline cellulose
- acyclovir
- Prior art date
Links
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title claims abstract description 86
- 229960001169 brivudine Drugs 0.000 title claims abstract description 82
- 206010036376 Postherpetic Neuralgia Diseases 0.000 title claims abstract description 27
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
- 235000019359 magnesium stearate Nutrition 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 239000008213 purified water Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960001021 lactose monohydrate Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims 3
- 229940008126 aerosol Drugs 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 abstract description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 45
- 229960004150 aciclovir Drugs 0.000 description 42
- 239000003826 tablet Substances 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- 239000002994 raw material Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 206010037844 rash Diseases 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960004396 famciclovir Drugs 0.000 description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229940093257 valacyclovir Drugs 0.000 description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940086177 acyclovir 800 mg Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000009A ITMI20010009A1 (it) | 2001-01-03 | 2001-01-03 | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK9572001A3 SK9572001A3 (en) | 2003-03-04 |
| SK287043B6 true SK287043B6 (sk) | 2009-10-07 |
Family
ID=11446384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK957-2001A SK287043B6 (sk) | 2001-01-03 | 2001-07-04 | Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie |
Country Status (20)
| Country | Link |
|---|---|
| AT (1) | AT6141U1 (da) |
| BE (1) | BE1014522A5 (da) |
| CH (1) | CH695662A5 (da) |
| CZ (1) | CZ20012464A3 (da) |
| DK (1) | DK177084B1 (da) |
| ES (1) | ES2192456B1 (da) |
| FI (1) | FI20011446A (da) |
| FR (1) | FR2818907B1 (da) |
| GB (1) | GB2370771A (da) |
| GR (1) | GR1004012B (da) |
| HR (1) | HRPK20010345B3 (da) |
| HU (1) | HUP0102816A3 (da) |
| IE (1) | IE20010413A1 (da) |
| IT (1) | ITMI20010009A1 (da) |
| NL (1) | NL1018431C2 (da) |
| PL (1) | PL348480A1 (da) |
| PT (1) | PT102642B (da) |
| SE (1) | SE0102309L (da) |
| SK (1) | SK287043B6 (da) |
| UA (1) | UA76402C2 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239527B1 (es) * | 2004-03-01 | 2006-11-16 | M. Cruz Fernandez Gonzalez | Composicion farmacologica de uso topico para el tratamiento del herpes zoster. |
| CN113712928A (zh) * | 2021-09-29 | 2021-11-30 | 重庆市力扬医药开发有限公司 | 经口腔粘膜吸收的溴夫定药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0104857A1 (en) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
| IT1170232B (it) * | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
| US5446031A (en) * | 1991-04-24 | 1995-08-29 | Yamasa Shuyu Kabushiki Kaisha | 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives |
| DK0874631T3 (da) * | 1996-01-19 | 2004-03-22 | Glaxo Group Ltd | Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse |
-
2001
- 2001-01-03 IT IT2001MI000009A patent/ITMI20010009A1/it unknown
- 2001-04-25 IE IE20010413A patent/IE20010413A1/en not_active IP Right Cessation
- 2001-05-01 GB GB0110682A patent/GB2370771A/en not_active Withdrawn
- 2001-05-11 HR HR20010345A patent/HRPK20010345B3/xx not_active IP Right Cessation
- 2001-05-29 CH CH00987/01A patent/CH695662A5/de not_active IP Right Cessation
- 2001-06-28 SE SE0102309A patent/SE0102309L/ not_active Application Discontinuation
- 2001-06-29 FR FR0108596A patent/FR2818907B1/fr not_active Expired - Lifetime
- 2001-06-29 DK DKPA200101019A patent/DK177084B1/da not_active IP Right Cessation
- 2001-07-02 NL NL1018431A patent/NL1018431C2/nl not_active IP Right Cessation
- 2001-07-03 FI FI20011446A patent/FI20011446A/fi not_active Application Discontinuation
- 2001-07-04 BE BE2001/0452A patent/BE1014522A5/fr not_active IP Right Cessation
- 2001-07-04 SK SK957-2001A patent/SK287043B6/sk not_active IP Right Cessation
- 2001-07-04 UA UA2001074658A patent/UA76402C2/uk unknown
- 2001-07-04 CZ CZ20012464A patent/CZ20012464A3/cs unknown
- 2001-07-05 ES ES200101566A patent/ES2192456B1/es not_active Expired - Fee Related
- 2001-07-05 PT PT102642A patent/PT102642B/pt active IP Right Grant
- 2001-07-05 HU HU0102816A patent/HUP0102816A3/hu unknown
- 2001-07-05 GR GR20010100322A patent/GR1004012B/el unknown
- 2001-07-05 PL PL01348480A patent/PL348480A1/xx not_active Application Discontinuation
-
2002
- 2002-07-03 AT AT0805702U patent/AT6141U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE0102309D0 (sv) | 2001-06-28 |
| SK9572001A3 (en) | 2003-03-04 |
| BE1014522A5 (fr) | 2003-12-02 |
| HRPK20010345B3 (en) | 2005-02-28 |
| GR1004012B (el) | 2002-11-01 |
| ITMI20010009A0 (it) | 2001-01-03 |
| HU0102816D0 (en) | 2001-09-28 |
| GR20010100322A (el) | 2002-10-08 |
| GB0110682D0 (en) | 2001-06-20 |
| AT6141U1 (de) | 2003-05-26 |
| PT102642B (pt) | 2003-06-30 |
| SE0102309L (sv) | 2002-07-04 |
| GB2370771A (en) | 2002-07-10 |
| FI20011446A0 (fi) | 2001-07-03 |
| PL348480A1 (en) | 2002-07-15 |
| PT102642A (pt) | 2002-07-31 |
| CH695662A5 (de) | 2006-07-31 |
| IE20010413A1 (en) | 2003-04-16 |
| HUP0102816A2 (en) | 2002-10-28 |
| HRP20010345A2 (en) | 2003-08-31 |
| FI20011446A (fi) | 2002-07-04 |
| HUP0102816A3 (en) | 2005-01-28 |
| FR2818907A1 (fr) | 2002-07-05 |
| DK200101019A (da) | 2002-07-04 |
| NL1018431C2 (nl) | 2002-07-05 |
| DK177084B1 (da) | 2011-07-11 |
| ES2192456A1 (es) | 2003-10-01 |
| ITMI20010009A1 (it) | 2002-07-03 |
| UA76402C2 (en) | 2006-08-15 |
| CZ20012464A3 (cs) | 2002-08-14 |
| FR2818907B1 (fr) | 2006-05-26 |
| ES2192456B1 (es) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101697800B1 (ko) | 니타족사니드의 서방성 제약 제형 | |
| AU2006325404B2 (en) | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit | |
| PL201411B1 (pl) | Zastosowanie entekawiru do wytwarzania kompozycji farmaceutycznej | |
| US20170080011A1 (en) | Use of nadh and nmn in preparation of drugs or health-care products for treating parkinson's disease | |
| AU2022252766B2 (en) | Treatment of hand eczema | |
| CN115645433A (zh) | 一种阿兹夫定替诺福韦二吡呋酯复方制剂及制备方法和应用 | |
| CA2835272A1 (en) | Pharmaceutical antiretroviral composition | |
| UA64761C2 (uk) | Фармацевтична композиція, що містить інгібітор альдегідредуктази та інгібітор ангіотензинперетворюючого ферменту | |
| CN115813874B (zh) | 一种口服三方组合降糖双释片的制备方法及其制剂 | |
| US20030166696A1 (en) | Pramipexole for the treatment of HIV dementia | |
| SK287043B6 (sk) | Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie | |
| SK284286B6 (sk) | Farmaceutický prostriedok, obsahujúci lamivudín a zidovudín, spôsob jeho výroby a jeho použitie | |
| SK1272003A3 (en) | Medicaments containing cilansetron for treating non-obstipated male IBS patients | |
| JPH07507280A (ja) | （−）−メトリフォネート含有薬剤 | |
| US20230055208A1 (en) | A pharmaceutical oral dosage form of q203 | |
| US20240041882A1 (en) | Mini-tablet dosage form of a viral terminase inhibitor and uses thereof | |
| KR100709531B1 (ko) | 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물 | |
| SI20854A (sl) | Farmacevtska zmes z učinkovino Brivudine z enkratnim dnevnim doziranjem | |
| CN114401724B (zh) | 一种降糖药物组合物 | |
| CN112569356B (zh) | 一种含有利尿剂的药物组合物 | |
| RO121585B1 (ro) | Utilizarea brivudinei în tratamentul infectiilor de tip herpes zoster sau nevralgiei post-herpetice | |
| EA005497B1 (ru) | Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций | |
| CN118059049A (zh) | 一种制剂组合物及其用途 | |
| WO2023091107A1 (en) | Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19 | |
| TR2021018192A1 (tr) | Anti̇-vi̇ral etki̇ gösterebi̇lecek yeni̇ i̇laç formülasyonlarinin hazirlanmasi ve covi̇d-19?a karşi etki̇si̇ni̇n araştirilmasi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20210704 |